Evidence further supporting estrogen’s role in the EMT of endometrial cancer include the increased expression of the transcriptions factors SNAIL, SLUG, and ZEB2 and mesenchymal markers N-cadherin and Vimentin, the decreased expression of the epithelial marker E-cadherin and activation of the PI3K and ERK signaling pathways in endometrial cancer cell lines treated with estradiol (20–22, 24, 26). Here, ZEB2 is linked to endometrial cancer.